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Abstract
Evidence exists that breast tumors differing by estrogen receptor (ER) and progesterone receptor
(PR) status may be phenotypically distinct diseases resulting from dissimilar etiologic processes.
Few studies have attempted to examine the association of physical activity with breast cancer subtype.
Such research may prove instructive into the biological mechanisms of activity. Consequently, this
investigation was designed to assess the relationship between physical activity and hormone receptor-
defined breast cancers in a population of Asian women in which the distribution of receptor types
differed from traditional Western populations. Participants, ages 25 to 64 years, were recruited into
this population-based, case-control study of breast cancer conducted in Shanghai, China from August
1996 to March 1998. Histologically confirmed breast cancer cases with available receptor status
information (n = 1001) and age frequency-matched controls (n = 1,556) completed in-person
interviews. Polytomous logistic regression was used to model the association between measures of
activity with each breast cancer subtype (ER+/PR+, ER−/PR−, ER+/PR−, and ER−/PR+) using the
control population as the reference group. Exercise in both adolescence and the last 10 years was
associated with a decreased risk of both receptor-positive (ER+/PR+) and receptor-negative (ER−/
PR−) breast cancers in both premenopausal and postmenopausal women (odds ratios, 0.44 and 0.51
and 0.43 and 0.21, respectively). Sweating during exercise within the last 10 years was also associated
with decreased risk for receptor-positive and receptor-negative breast cancers among post-
menopausal women (odds ratios, 0.58 and 0.28, respectively). These findings suggest that physical
activity may reduce breast cancer risk through both hormonal and nonhormonal pathways.
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Introduction
On a global scale, breast cancer is the most frequently diagnosed cancer among women,
accounting for ~23% of all cancers (1). Incidence rates of breast cancer among Chinese women
have traditionally been roughly one third the rate of women in Western populations, such as
the United States (18.7/100,000 versus 99.4/100,000; ref. 1). Recent evidence, however, has
revealed that breast cancer rates seem to be climbing in China at ~3% to 4% yearly, especially
within urbanized regions, such as Shanghai (1).
Many biological markers have been shown to have a significant effect on breast cancer relapse
and, ultimately, death (2). Among these are estrogen receptor (ER) and progesterone receptor
(PR) status of the tumor at diagnosis (3–6). Previous research shows that hormone-related
factors, such as age at menarche, parity, and age at menopause, tend to be associated with
receptor-positive (ER+/PR+) breast cancer, whereas family history of breast cancer and
cigarette smoking have been associated with receptor-negative (ER−/PR−) breast cancer (7–
16). These findings suggest that breast cancer does not represent a single phenotype (i.e., that
it is not a homogeneous disease) but rather a heterogeneous set of diseases with perhaps
different genetic and environmental determinants.
The majority of published studies (17–20) have indicated that high levels of physical activity
confer a protective effect on breast cancer with proposed biological mechanisms ranging from
hormone modulation to up-regulated immune functioning (21). Interestingly, the association
between physical activity and breast cancer has not been seen consistently across all studies
(22–33), with some studies showing either a null or a positive (i.e., detrimental) effect of
physical activity on breast cancer risk.
One area that has not been studied extensively that could explain some of these conflicting
reports is the association of physical activity with hormone receptor-defined breast cancer.
Thus, it is possible that physical activity may be differentially associated with the various types
of receptor-defined breast cancers. Furthermore, characterizing these associations may provide
useful clues that will extend our understanding of the mechanism of action of physical activity
on breast cancer. The Shanghai Breast Cancer Study (SBCS) offered a unique opportunity to
examine this hypothesis among a population of women with a different distribution of hormone
receptor subtype than more traditional Western populations. Previous research in the SBCS
concluded that lifetime physical activity was associated with a significant reduction in overall
breast cancer risk (30). Within the United States, typically only ~10% of all breast tumors are
receptor negative; however, 26% of the breast tumors in the SBCS were receptor negative. The
greater frequency lends greater power to stratified analyses of breast cancer receptor type.
Consequently, the purpose of this investigation was to examine the association between
physical activity and breast cancer by receptor status among women participating in the SBCS.
Materials and Methods
Subjects in this study were recruited from August 1996 to March 1998 as part of the SBCS, a
population-based, case-control study of breast cancer conducted in urban Shanghai, China
(30,34). The SBCS protocol was approved by the relevant institutional review boards and
informed consent was obtained from all study participants.
Subjects
All participants were permanent residents of Shanghai and were ages 25 to 64 years during the
study period. Histologically confirmed breast cancer cases were recruited via a rapid case-
ascertainment system of the Shanghai Cancer Registry. A total of 1,602 individuals with breast
cancer were determined to be eligible for the study (alive at the time of interview and having
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no prior history of cancer). Of these, 1,459 (92% of those eligible) women completed the in-
person interview. Refusal, death, or inability to locate the subject were the primary reasons for
nonparticipation.
Female controls were recruited randomly from the general population of Shanghai through a
resident registry system. Controls were frequency matched to cases on age by 5-year interval.
Data were obtained on 1,556 women (90.3% of the 1,724 eligible), with refusal (9.6%) as the
primary reason for nonparticipation.
Study Procedures
Data Collection: Trained interviewers administered a structured questionnaire designed to
collect information on basic demographics: menstrual, reproductive, medical, family, and
weight history; hormone usage; diet; physical activity behaviors; and alcohol use. For the case
subjects, the average time between diagnosis and interview was 5 months. At the time of
interview, current body measurements, including weight and height, were obtained on all
participants using standard protocols. Participants were instructed to wear light clothing. Shoes
were removed for the height measurements but not for weight measurements. Height and
weight were measured twice. A third measurement was taken if the difference between the first
two measures was significant (>1 kg for weight and >1 cm for height). The average of the two
measures was used for this analysis.
Physical Activity: Information on occupational, household, transportation, and leisure-time
physical activity was ascertained on all participants. Occupational activity was based on
standardized job classifications (30) for all positions held by an individual woman for at least
3 years. Due to the stability of occupations within China, this period is adequate to capture the
majority of occupations held by the individual (30). The average number of jobs held by women
in this population was 2, whereas the average duration of a single job was 14.3 years. Subjects
also reported the number of years spent at each job as well as estimates of total time spent
standing or walking per day. Time spent sitting and average energy expenditure were classified
into three levels (high, medium, or low) using job codes from the >200 occupations reported
(30). For example, occupations, such as clerk or accountant, would have a “high” sitting and
a “low” energy expenditure classification. This classification was then multiplied by the
number of years spent on the job; the scores for each job were then summed to create overall
scores for time spent sitting, average energy expenditure, and physical activity level (self-
evaluation). Total occupational standing or walking time was calculated by multiplying the
reported time spent standing or walking for each job by the duration of the job and then
summing the values across all jobs.
Participants reported on their household, transportation, and leisure-time physical activity in
adolescence (ages 13–19 years) and adulthood (last 10 years before the interview date).
Transportation (biking and walking) and household physical activity were reported as the total
time (per day or week) spent in each activity domain [i.e., “how many hours per day did you
spend on housework?” and “how many minutes did you walk each day (including walking to
work, shopping, sending, or picking up children)?”]. For leisure-time activity estimates,
subjects indicated the five most common sports activities in which they participated in the
period of interest. Duration (per week) estimates were obtained for all reported activities. From
these variables, summary estimates [metabolic equivalent (MET)-hours/d/y] for physical
activity were created using the standard MET classifications (35,36). Based on responses to
the sports questions, a single lifetime activity variable was created with four groups: activity
in adolescence and adulthood, no activity in adolescence or adulthood, activity in adolescence
but not adulthood, and no activity in adolescence but reported in adulthood. Participants also
were asked to rate the amount of time spent in leisure activity in comparison with other persons
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using a Likert-type response (i.e., “more than average,” “a little more than average,” “about
average,” “a little less than average,” and “less than average”). For those reporting leisure-time
activity, respondents were asked to evaluate the frequency of sweating during exercise (i.e.,
“sweated every time,” “sweated most of the time,” or “normally did not sweat”).
ER and PR Status: Data on ER and PR status based on medical record review were available
for 1,001 (69%) of the 1,459 breast cancer cases. Only qualitative values (positive or negative)
were collected. ER and PR status were designated as either positive or negative resulting in
the following joint categories: ER+/PR+ (receptor-positive), ER−/PR+ (mixed), ER+/PR−
(mixed), and ER−/PR− (receptor-negative).
Statistical Methods
All analyses were conducted using SAS (version 9.1) and an α, type I error, level of 0.05 (two-
tailed) for statistical tests. The distributions or frequency of all variables were reviewed and
descriptive statistics were computed. The distributions for leisure-time physical activity in
adolescence and adulthood were highly skewed approximating a χ2 distribution. To attenuate
the leverage effect of the few observations in the higher range and to simplify the interpretation
of these findings, the variables were categorized. All nonexercisers were classified as 0. The
exercising group was categorized as greater than or equal to or less than the median value (1.92
MET-hours/d/y for adolescence and 0.875 MET-hours/d/y for adulthood) for the control
population. Other physical activity variables included a comparison of time spent in activity
relative to others, sweating during exercise, lifetime activity, occupational sitting, occupational
walking, occupational activity self-rating, average occupational energy expenditure, household
activity, and walking for transportation. Polytomous logistic regression was used to model the
relationship between the physical activity summary variable and breast cancer tumor subtype
(37), with the control group as the reference population. Each physical activity variable was
assessed in a separate model. Due to the potential biological differences, effect modification
of physical activity by menopausal status was assessed by including an interaction term in
initial models. Because many of the Ps of the Wald statistic for these interaction terms showed
marginal significance, all models were stratified by menopausal status and adjusted for those
variables that previous analysis using polytomous logistic modeling found to be significantly
associated with breast cancer subtype. Models among premenopausal women were adjusted
for current age, age at first menarche, age at first birth, parity, and breast-feeding, whereas
postmenopausal models were adjusted for these previous variables and for age at menopause.
For women who were nulliparous, the value for the variable “months of breast-feeding” was
set as 0 and the value for the variable “age at first live birth” was designated as either current
age (for premenopausal women) or age at menopause (for postmenopausal women). Body mass
index [weight (kg)/height (m2)] was included in all initial models; yet, all point estimates
remained unchanged (<10% difference in b estimates) with no evidence for confounding or
effect modification. Thus, final models excluded this variable. Results are presented as odds
ratios (OR).
Results
Of the breast cancer cases, 529 (53%) of 1,001 with known ER/PR status were receptor-
positive, 259 (26%) were receptor-negative, 108 (11%) were ER+/PR−, and 105 (10%) were
ER−/PR+. Population characteristics are described in Tables 1 and 2. Most variables showed
similar distributions among the five groups. As might be expected, controls tended to have a
lower frequency of a family history of breast cancer and were less likely to have a personal
history of fibroadenoma among premenopausal women. Among postmenopausal women,
many of the body habitus measures tended to be lowest for the control group. For most of the
physical activity measures, the case groups reported less physical activity than did controls
Adams et al. Page 4
Cancer Epidemiol Biomarkers Prev. Author manuscript; available in PMC 2010 October 28.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
among premenopausal women. This pattern was less consistent among premenopausal women,
with case groups reporting greater levels of activity for some of the measures.
Consistent with previous reports from this study (30), physical activity showed a protective
effect on overall breast cancer risk (results were not stratified by ER and PR type). Activity in
both adolescence and within the last 10 years resulted in a 48% decrease (Ps < 0.01) in risk
for premenopausal women and a 63% decrease (Ps < 0.0001) for postmenopausal women.
Other activity variables for which a statistically significant protective effect on overall breast
cancer risk was observed included sweating during exercise within the last 10 years, leisure
activity measured by MET-hours/d/y, and self-comparison (data not shown).
The multivariable-adjusted estimates of the association of leisure-time activity with each breast
cancer hormone receptor type are presented for premenopausal and postmenopausal women
in Tables 3 and 4, respectively. The majority of point estimates showed a trend for a protective
effect for physical activity on all tumor types, with this effect achieving statistical significance
for several physical activity measures (MET-hours/d/y, sweating during exercise, and lifetime
activity). Most notable is that premenopausal women who reported exercise in both
adolescence and during the last 10 years showed a significant decreased risk by 66% for
receptor-positive breast cancer and 49% for receptor-negative breast cancers. Given that power
was limited among many of the strata due to small sample sizes, it is worth noting that many
indices of physical activity (self-comparison and sweating during exercise) showed a
marginally significant protective effect with all four breast cancer types. Because multiple
significant associations were found between leisure-time activity and breast cancer type, we
concluded that the overall pattern of association was similar for receptor-positive and receptor-
negative breast cancers. Furthermore, the point estimates themselves were often very similar.
The homogeneity between tumor types was even more apparent among postmenopausal
women (Table 4). Leisure-time physical activity in both adolescence and the last 10 years was
protective for receptor-positive and negative breast cancers (ORs, 0.16–0.58). Additional
exercise measures, such as self-comparison, sweating, and lifetime activity, showed a
protective effect for three of the four tumor types. Activity in adolescence, the last 10 years,
or both was protective for receptor-positive breast cancer with risk reductions ranging from
40% to 57%. Only activity in the last 10 years or during both adolescence and the last 10 years
resulted in a reduction in risk by 62% to 79% for receptor-negative breast cancer. Activity in
adulthood only was marginally associated with the ER+/PR− type. As with premenopausal
women, activity was significantly associated with both receptor-positive and receptor-negative
breast cancers. Interestingly, several significant associations were observed between some of
the measures of activity (MET-hours/d/y, self-comparison, and sweating during exercise) and
ER+/PR− breast cancer among postmenopausal women but not premenopausal women. Due
to the greater number of significant associations, there was stronger evidence for homogeneity
between receptor types among postmenopausal women.
The patterns of association for the groups were less consistent for occupational, household,
and transportation-related activity (Tables 5 and 6). A statistically significant effect was only
achieved for some measures of occupational and household activity. If one considers the
associations that attained marginal significance, there seems to be greater consistency in pattern
between the receptor-positive and the receptor-negative groups for occupational activity
among premenopausal women. Overall, however, no consistent pattern of association is
discernable.
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Discussion
In this population of Chinese women, physical activity exposures were inversely associated
with breast cancer regardless of receptor status. It should be noted that the association seemed
to be less consistent across exposures for mixed receptor types. However, this may be a result
of the small sample sizes in these groups. These findings suggest that physical activity may
influence breast cancer risk, in part, through nonhormonal and more general pathways (e.g.,
insulin-related or growth factor–mediated pathways).
Results from this study are similar to those found by Enger et al. (33). Recreational physical
activity was associated with a 30% to 60% reduction in risk for all tumor types when comparing
the highest tertile with nonexercisers among premenopausal and postmenopausal women.
When comparing numbers of subjects, it is worth noting that the present study had greater
numbers of premenopausal breast cancers, whereas the Enger et al. study had a greater number
of post-menopausal breast cancers. Both Lee et al. and Britton et al. found no evidence for a
differential effect of physical activity by receptor type either; however, the overall relationship
between physical activity and breast cancer in these studies was null (28,38). Furthermore,
these studies only assessed recreational activity and had no estimates of occupational,
household, or transportation-related activity as described in our investigation.
It is interesting to note that the effect of activity seemed to be modified by menopausal status
as evidenced by the significance of the interaction term between some measures of activity and
menopausal status. The protective effect seemed to be greater among postmenopausal women
than premenopausal women. This suggests that the etiologic role of activity may differ by
menopausal status. Alternatively, this may underscore possible differences in the composition
of total daily physical activity by menopausal status. For example, occupational activity may
comprise a greater proportion of total activity among premenopausal women, whereas
household activity may contribute greater to total activity among postmenopausal women.
The results from this investigation provide important clues into the biological mechanism for
the association between physical activity and breast cancer. If activity functioned solely
through hormonal mechanisms, we would expect to see significant associations only among
receptor-positive breast cancers. This has been shown previously for reproductive (i.e.,
hormone-related) risk factors that differentially associate with receptor-positive tumors cancer
(7–16). The significant associations shown for receptor-negative cancers suggest that
nonhormonal mechanisms may also play a role in the protective effect of activity.
Some animal studies provide clues that physical activity may act through nonhormonal
mechanisms to affect breast cancer risk. In a study by Westerlind et al. (39), female Sprague-
Dawley rats were exercised 30 minutes a day for 5 days a week starting at 28 days of age. A
subset of animals was sacrificed at 28, 42, 56, 70, and 84 days. Sedentary rats were given a
sham exercise protocol in which the animals were placed on the exercise wheel for the same
duration. Although no carcinogen was given, changes in breast and other tissues were
documented. No differences were noted between groups in relationship to growth, sexual
maturation, steroid hormones, or number of mammary terminal end buds. This is in contrast
to what might be expected if physical activity affected hormonal pathways alone. On the other
hand, cellular proliferation and apoptosis in mammary tissues were increased significantly in
the exercised animals. Westerlind et al. suggest that this might result in increased cellular
turnover with quicker removal of preneoplastic cells. They also hypothesize that this same
mechanism might lead to accelerated terminal differentiation of the mammary gland,
effectively decreasing the period that cells would be susceptible to carcinogenic insult. It is
worth reiterating that this study did not follow the animals for breast neoplasm development.
However, to the extent that physical activity has shown an association with breast cancer risk
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in human studies, there is indirect evidence in animal studies that physical activity may have
nonhormonal causal pathways to reduce breast cancer risk.
In addition to these cellular mechanisms, several other nonhormonal biological pathways have
been proposed to explain the inverse association between physical activity and breast cancer
(21). One such mechanism involves insulin-like growth factor-I (IGF-I). IGF-I is a potent
stimulator of cell growth in in vitro studies. In human studies, a meta-analysis by Fletcher et
al. found evidence for a positive association between IGF-I and IGF-I-binding protein-3 and
breast cancer risk (40). Indeed, IGF-I has been found associated with increased risk for breast
cancer in the very same population under study in this investigation (41). Physical activity has
been found to decrease hyperinsulinemia and insulin resistance, which could result in decreased
bioavailable IGF-I, thereby lowering breast cancer risk (42,43). In this population of women,
IGF-I levels decreased as age increased with higher levels observed among premenopausal
women than among postmenopausal women (44), yet control subjects had lower levels of IGF-
I in comparison with case subjects among both premenopausal and postmenopausal women.
It is possible that the greater consistency of association between activity measures and breast
cancer type (as evidenced by a greater number of significant associations) among
postmenopausal women may be attributable, in part, to the chronic effects of physical activity
on IGF-I levels.
Other hypothesized mechanisms involve increased immune surveillance (45). Up-regulation
of natural killer cell numbers and activity and increased immune surveillance have been
documented in athletes (46). Still, other mechanisms may involve a synergy between hormonal
and nonhormonal mechanisms. In another study of the SBCS, the breast cancer risk estimate
for women with both high estrone and IGF-I levels exceeded the estimate for either one of
these biomarkers alone (47).
As with any epidemiologic study, there are potential limitations that should be noted. As is
common with this type of research, the method of quantification of ER and PR status may not
have been standard for all case participants. It is possible that different hormone receptor assay
methods were used among cases. Hence, there may have been some misclassification of
hormone receptor status. Although it is impossible to state with certainty, it is more likely that
this type of misclassification would be nondifferential and would bias study findings toward
a finding of no difference between receptor groups. Overall, the threat of this weakness to the
validity of our central findings in this report is low; therefore, we believe our significant
findings to be indicative of true relationships. It is also worth noting that ER and PR status was
missing on 31% of the participants of the SBCS. To assess possible selection bias, we compared
the cases included in the analysis with cases excluded due to missing information (data not
shown). There were no statistical differences between the two groups for all the physical
activity variables, except for occupational sitting time (cases included had a higher mean
occupational sitting time than those excluded). Thus, we found no evidence for bias from the
selection of cases for the analysis.
Among case-control studies are concerns of selection and recall bias. High participation rates
for both cases (92%) and controls (90%) in this study minimized potential biases related to
selection among controls. However, given that cases were interviewed at diagnosis or
immediately afterward, the possibility exists that they may have reported their physical activity
behaviors differently than controls. If cases believed that there was an inverse relationship
between physical activity and breast cancer, they may have underreported their activity levels
relative to controls. We are not able to evaluate this potential bias directly in this study;
however, results from several prospective studies, which should be immune to recall biases,
have reported inverse associations between physical activity and breast cancer (48–52).
Regardless, this type of bias would most likely serve to influence measures of association
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toward a null finding, thereby strengthening the claim of a true association. Finally, the physical
activity questionnaire employed in this research may not have provided a precise estimate of
all levels and types of activities evaluated. It is well known that physical activity behaviors are
measured with substantial error and nondifferential misclassification resulting from
measurement error would function to attenuate any measures of association. A validation study
examining the reliability and validity of a similar questionnaire (without an occupational
activity assessment) found the majority of items used in this research to be sufficiently valid
to stratify women into low and high activity levels (53).
This investigation also has many strengths. Although sample size has been proven to be limiting
in some analyses, this is one of the largest studies of its kind, with one of the largest populations
of receptor-negative breast cancers. A recently published study by Colditz et al. (54) included
2,096 breast cancer cases stratified by receptor type; however, no measures of physical activity
were evaluated. Results obtained from this investigation confirm the findings of other studies
and offer unique insights into the possible underlying biological mechanism(s) associating
physical activity with breast cancer.
In conclusion, physical activity seemed to be inversely associated with breast cancer risk
regardless of hormone receptor type. Similar patterns of association were shown between both
receptor-positive and receptor-negative breast cancers. These findings need to be confirmed
in other ethnic populations, such as Hispanic Americans and African Americans, who tend to
have a higher rate of hormone-negative tumors (55), higher-risk tumors for a given stage (and
concomitantly poorer survival; ref. 56), and very low rates of physical activity. (57)
Additionally, future work should focus on the possible biological mechanisms of the physical
activity/breast cancer association, including both hormonal and nonhormonal factors.
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